Skip to content
Question
What will a month cost?
Read
7 min
Updated
November 2026

Retatrutide Cost: No Approved Product, No Lawful Compounded Route, No Price

FDA states that retatrutide cannot be used in compounding under federal law, and it appears on neither bulk substances list. What the phase 2 and phase 3 trials measured, who the agency has warned, and what can actually be priced instead.

ByJenna PrattConsumer-access reporterPublished Updated

A search for what retatrutide costs has an answer, and it is not a dollar figure. There is no approved retatrutide product in the United States, no compounded route a pharmacy may lawfully use, and therefore no lawful price to compare. What exists instead is a late-stage trial program, a gray market that quotes numbers anyway, and a set of federal statements about both. Those are worth reading before paying anyone.

What FDA says, in its own words

On its page about unapproved GLP-1 drugs used for weight loss, FDA gives retatrutide a heading, shared with cagrilintide, and one sentence: retatrutide and cagrilintide cannot be used in compounding under federal law[1].

The sentence after it adds two facts. They are not components of FDA-approved drugs, and they have not been found safe and effective for any condition[1].

That first clause is the legal hinge. The compounding exemption for a bulk substance runs through being a component of an approved drug, or appearing on a list FDA maintains, and retatrutide is neither.

The 503A bulk substances list, updated May 14, 2026, does not name it in any of its three categories[2]. The 503B list for outsourcing facilities, updated March 21, 2025, does not name it either[3].

How the two lists differ is set out in 503A vs 503B on this site. Neither list has an entry under the molecule’s name or under its development code.

Who FDA has warned about it

The same page names three groups the agency has already written to over this molecule, which is a better description of the market than any price would be.

It has warned telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers[1].

It has warned active pharmaceutical ingredient distributors for selling retatrutide and other GLP-1 drugs to compounders, and outsourcing facilities for repackaging retatrutide[1].

Separately, it has warned companies that illegally sold unapproved drugs falsely labeled “for research purposes” or “not for human consumption”, the convention the RUO peptides article explains[1]. The drugs contained semaglutide, tirzepatide, retatrutide, survodutide or mazdutide, and were sold to consumers with dosing instructions[1].

What the trials have measured

The evidence is real, which is part of why the demand is. A phase 2, double-blind, randomized, placebo-controlled trial enrolled 338 adults with a body-mass index of 30 or higher, or 27 to under 30 with a weight-related condition[4].

Participants received subcutaneous retatrutide at 1, 4, 8 or 12 mg, or placebo, once weekly for 48 weeks[4].

Least-squares mean percentage change in body weight at 48 weeks, phase 2 trial
GroupChange in body weight
Retatrutide 1 mg−8.7%
Retatrutide 4 mg (combined)−17.1%
Retatrutide 8 mg (combined)−22.8%
Retatrutide 12 mg−24.2%
Placebo−2.1%
Least-squares mean percentage change in body weight at 48 weeks, phase 2 trial. Jastreboff and colleagues, New England Journal of Medicine, 2023; 338 adults, 48 weeks, funded by Eli Lilly.

The trial was funded by the manufacturer, and several authors were its employees[4]. The most common adverse events were gastrointestinal, dose-related and mostly mild to moderate, and dose-dependent increases in heart rate peaked at 24 weeks before declining[4].

Phase 3 has followed. The master protocol registered as TRIUMPH-1, a randomized, double-blind, placebo-controlled trial in participants without type 2 diabetes who have obesity or overweight, enrolled 2,335 people and reached primary completion on April 6, 2026[5].

No one can yet quote a retatrutide month the way Zepbound price quotes one. A completed phase 3 trial is not an approval, and an approval is not a price. Both still have to happen first.

What can be priced today

The guide to tirzepatide compounding rules explains how the end of the shortage changed the rules for compounded tirzepatide. Compounded semaglutide and tirzepatide both have published markets, computed from every seller that publishes a monthly price. Each brand also has a maker’s own self-pay price to set against it.

The compounded semaglutide cost and compounded tirzepatide cost pages, and tirzepatide vs semaglutide cost, set out those figures. The molecules with an approved product or a lawful compounded route are the ones with a real figure attached.

The whole point of a comparison is that the figures are comparable.

FAQ

5 questions

How much does retatrutide cost?

There is no lawful US price. No approved retatrutide product exists, and FDA states that retatrutide cannot be used in compounding under federal law, so no pharmacy can quote a compounded month for it either.

Why can a compounding pharmacy not make retatrutide?

The compounding exemption for a bulk substance runs through the substance being a component of an approved drug or appearing on a list FDA maintains. FDA states that retatrutide is not a component of an approved drug, and it is named on neither the 503A nor the 503B bulk substances list.

What are the sites selling retatrutide?

FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, ingredient distributors for selling it to compounders, outsourcing facilities for repackaging it, and companies selling it labeled for research purposes or not for human consumption while giving consumers dosing instructions.

How well did retatrutide work in trials?

In a 48-week phase 2 trial of 338 adults funded by the manufacturer, least-squares mean body weight change was −8.7% at 1 mg, −17.1% at 4 mg, −22.8% at 8 mg and −24.2% at 12 mg, against −2.1% on placebo.

When will retatrutide be available?

No approval date is published. Its phase 3 program is under way, and the master protocol registered as TRIUMPH-1 enrolled 2,335 participants and reached primary completion on April 6, 2026. A completed trial is not an approval, and an approval is not a price.

Sources

5 cited
  1. [1]Food and Drug Administration (2026). FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration. Source
  2. [2]Food and Drug Administration (2026). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. Source
  3. [3]Food and Drug Administration (2025). Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (updated March 21, 2025) U.S. Food and Drug Administration. Source
  4. [4]Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial New England Journal of Medicine. PMID 37366315
  5. [5]Eli Lilly and Company (2026). A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1) ClinicalTrials.gov, NCT05929066. Source